An investigation on behalf of current long term investors in Accelerate Diagnostics Inc (NASDAQ:AXDX shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:AXDX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/02/2015 -- An investigation on behalf of current long-term investors in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) concerning potential breaches of fiduciary duties by certain directors and officers of Accelerate Diagnostics Inc was announced.
Investors who are current long term investors in Accelerate Diagnostics Inc (NASDAQ:AXDX) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ:AXDX stocks follows a lawsuit filed recently against Accelerate Diagnostics Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:AXDX stocks, concerns whether certain Accelerate Diagnostics officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Arizona the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the defendants allegedly misrepresented and/or failed to disclose to investors that Accelerate Diagnostics' main product the ID/AST system, formally known as the BACcel system, requires a positive blood culture to diagnose pathogens in a blood sample.
On February 18, 2015, an article was published that asserted that Accelerate Diagnostics Inc falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture, while in reality, the test required a blood culture, a fact that significantly reduced the value of the technology. Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX0 declined to as low as $17.29 per share on February 23, 2015.
On May 29, 2015, NASDAQ:AXDX shares closed at $22.32 per share.
Those who purchased shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego